Bladder Botox Injections
Botox is also called Botulinum Toxin type A. It is used to help people with sensitive bladders, Overactive Bladder (OAB) and incontinence. It works by relaxing the bladder muscle allowing the bladder capacity to increase. The majority of patients respond well to the treatment and the effects can be life-changing.
Mr Parkinson's results, which have been published internationally, show a success rate of 85% (patients who described themselves as "very much improved" after treatment)
Over the last 7 years, we have monitored the success of Botox treatment in hundreds of patients. An ongoing audit of outcomes shows that 85% of patients treated by Mr Parkinson consistently report significant improvement in their symptoms. These are all patients who have failed to improve with other treatments and medications.
Botox has been used in cosmetic surgery for many years to help relax facial muscles and reduce the appearance of wrinkles. Botox works on the nerve endings of muscles, blocking the release of the chemical that causes the muscle to contract.
In patients with an overactive bladder, the bladder muscle often squeezes at inappropriate times causing a desperate urge to pass urine or even incontinence. Botox injections help to reduce these bladder contractions, restoring control. When simple bladder exercises and tablets haven’t helped, Botox is an effective remedy which can be performed without the need for general anaesthetic. Mr Parkinson has performed over 2,500 Botox procedures in the last 10 years, most under local anaesthetic.
For more information, follow this link to the BAUS patient information leaflet on Botox bladder injections.
“Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox®) or abobotulinumtoxinA (Dysport®) make a difference?” Pravisha Ravindra, Benjamin L. Jackson and Richard J. Parkinson. 2013 BJU International doi:10.1111/bju.12028
“Intravesical Botulinum Toxin for Overactive Bladder Syndrome without Detrusor Overactivity.” Jackson BL, Burge F, Bronjewski E, Parkinson RJ. BJMSU 5(4), p169-73; 2012